The group will need longer-term data to justify its huge valuation.
The microbiome-focused group has some explaining to do.
Abelacimab justifies its spin-out into the Blackstone-backed private biotech Anthos Therapeutics, and a big deal could follow.
Lilly and Novo look set for a battle in glucose-sensitive insulin, and other areas too.
Animal toxicity findings with ARO-ENaC come not long after Ionis’s similar setback.